Grant: Engage Grants Program
Université du Québec à Montréal
$25,000.00
Application of organobismuth chemistry in the design and development of drug libraries
EF 2013-14
Résumé
Access to efficient drugs to treat diseases that affect Canadians is still among the highest priorities of oursociety. The development of new medicinal agents depends on the identification of small molecules that caninteract with biological targets that are involved in diseases. These small molecules are typically identified byscreening collections of synthetic compounds. Paraza Pharma Inc. is an innovative drug discovery companythat is involved in lead optimization of early drug candidates for unmet medical needs in alliance withbiotechnology and pharmaceutical companies. Currently, Paraza Pharma does not possess its own proprietarycompound collection and must therefore rely exclusively on commercial libraries of molecules for theirscreening campaigns. However, the diversity of commercial compound collections and the quality of theproducts that they contain is often mediocre and leads to bioactive molecules having poor physico-chemicalproperties, with the consequence of reducing the chances of success of developing new drugs. Thedevelopment of an original library of lead-like small molecules within Paraza Pharma would considerablyincrease the competive advantage of the organization. We have developed over the past years a portfolio ofreactions that involve organobismuth reagents and that lead to the formation of carbon-carbon,carbon-nitrogen, and carbon-oxygen bonds. In this project, we will utilize these reactions to install a widediversity of highly functionalized groups on medicinally relevant scaffolds. Using combinatorial chemistrytools, these reactions will then be applied in the preparation of drug-like libraries. The library of molecules thatwill be generated will be used by Paraza Pharma Inc. to identify molecules that can disrupt biochemicalprocesses by interacting with key biological targets. This project will help Paraza Pharma Inc. expand itsdiscovery platform that is used in their own programs or through collaborations with current or future clients,thus contributing to the creation of jobs and to the economy of Québec and Canada.
Programme
Engage Grants Program
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
NSERC's Awards Data
Tel que publié
Application id
453382-2013
Name nom
Gagnon, Alexandre
Department département
Chimie
Organization id
57
Institution établissement
Université du Québec à Montréal
Province en
Québec
Province fr
Québec
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2013
Competition year année de concours
2013
Award amount
25000
Program id
EGP
Program name en
Engage Grants Program
Program name fr
Programme de subventions d'engagement partenariat
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
1552
Committee name en
Quebec Internal Decision Committee
Committee name fr
Comité de décision interne pour le Québec
Area of application code
1201
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Life sciences (including biotechnology)
Area of application fr
Sciences de la vie (y compris biotechnologie)
Research subject code
3704
Research subject group en
Organic chemistry
Research subject group fr
Chimie organique
Research subject en
Synthetic methodology
Research subject fr
Méthodologie en synthèse
Partie
1
Nb partie
1
Application title
Application of organobismuth chemistry in the design and development of drug libraries
Keyword
NSERC
Application summary
Access to efficient drugs to treat diseases that affect Canadians is still among the highest priorities of oursociety. The development of new medicinal agents depends on the identification of small molecules that caninteract with biological targets that are involved in diseases. These small molecules are typically identified byscreening collections of synthetic compounds. Paraza Pharma Inc. is an innovative drug discovery companythat is involved in lead optimization of early drug candidates for unmet medical needs in alliance withbiotechnology and pharmaceutical companies. Currently, Paraza Pharma does not possess its own proprietarycompound collection and must therefore rely exclusively on commercial libraries of molecules for theirscreening campaigns. However, the diversity of commercial compound collections and the quality of theproducts that they contain is often mediocre and leads to bioactive molecules having poor physico-chemicalproperties, with the consequence of reducing the chances of success of developing new drugs. Thedevelopment of an original library of lead-like small molecules within Paraza Pharma would considerablyincrease the competive advantage of the organization. We have developed over the past years a portfolio ofreactions that involve organobismuth reagents and that lead to the formation of carbon-carbon,carbon-nitrogen, and carbon-oxygen bonds. In this project, we will utilize these reactions to install a widediversity of highly functionalized groups on medicinally relevant scaffolds. Using combinatorial chemistrytools, these reactions will then be applied in the preparation of drug-like libraries. The library of molecules thatwill be generated will be used by Paraza Pharma Inc. to identify molecules that can disrupt biochemicalprocesses by interacting with key biological targets. This project will help Paraza Pharma Inc. expand itsdiscovery platform that is used in their own programs or through collaborations with current or future clients,thus contributing to the creation of jobs and to the economy of Québec and Canada.